Treatment with sarilumab was associated with lower all-cause mortality compared with tocilizumab in adults with rheumatoid arthritis.

At week 52 in a randomized, controlled trial, results suggest that tocilizumab is more effective than methotrexate in ...

The combination of talquetamab (Talvey) and daratumumab (Darzalex) demonstrated promising and robust clinical activity for ...

Phase 2 data presented at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting show deep and durable tumor regressions in heavily pre-treated melanoma patients, with a mild safety ...

SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the research ...

Results from the trial's first year were reported at the 2024 ACR meeting, and they persuaded the FDA to approve the drug for ...

Familiarity with AstraZeneca’s Saphnelo and enthusiasm for next-generation biologics signal increasing optimism, though CAR T-cell therapy divides opinion amid safety and access concerns, according to ...

INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS ...

Eydenzelt is a vascular endothelial growth factor inhibitor referencing Eylea, which is jointly developed by Regeneron ...

Learn more about whether Biogen Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.